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Abstract
Background: At present, there is insufficient evidence to guide appropriate management of women with preterm prelabor
rupture of membranes (PPROM) near term.
Methods and Findings: We conducted an open-label randomized controlled trial in 60 hospitals in The Netherlands, which
included non-laboring women with .24 h of PPROM between 34
+0 and 37
+0 wk of gestation. Participants were randomly
allocated in a 1:1 ratio to induction of labor (IoL) or expectant management (EM) using block randomization. The main
outcome was neonatal sepsis. Secondary outcomes included mode of delivery, respiratory distress syndrome (RDS), and
chorioamnionitis. Patients and caregivers were not blinded to randomization status. We updated a prior meta-analysis on
the effect of both interventions on neonatal sepsis, RDS, and cesarean section rate. From 1 January 2007 to 9 September
2009, 776 patients in 60 hospitals were eligible for the study, of which 536 patients were randomized. Four patients were
excluded after randomization. We allocated 266 women (268 neonates) to IoL and 266 women (270 neonates) to EM.
Neonatal sepsis occurred in seven (2.6%) newborns of women in the IoL group and in 11 (4.1%) neonates in the EM group
(relative risk [RR] 0.64; 95% confidence interval [CI] 0.25 to 1.6). RDS was seen in 21 (7.8%, IoL) versus 17 neonates (6.3%, EM)
(RR 1.3; 95% CI 0.67 to 2.3), and a cesarean section was performed in 36 (13%, IoL) versus 37 (14%, EM) women (RR 0.98; 95%
CI 0.64 to 1.50). The risk for chorioamnionitis was reduced in the IoL group. No serious adverse events were
reported. Updating an existing meta-analysis with our trial results (the only eligible trial for the update) indicated RRs of
1.06 (95% CI 0.64 to 1.76) for neonatal sepsis (eight trials, 1,230 neonates) and 1.27 (95% CI 0.98 to 1.65) for cesarean section
(eight trials, 1,222 women) for IoL compared with EM.
Conclusions: In women whose pregnancy is complicated by late PPROM, neither our trial nor the updated meta-analysis
indicates that IoL substantially improves pregnancy outcomes compared with EM.
Trial registration: Current Controlled Trials ISRCTN29313500
Please see later in the article for the Editors’ Summary.
PLoS Medicine | www.plosmedicine.org 1 April 2012 | Volume 9 | Issue 4 | e1001208Citation: van der Ham DP, Vijgen SMC, Nijhuis JG, van Beek JJ, Opmeer BC, et al. (2012) Induction of Labor versus Expectant Management in Women with
Preterm Prelabor Rupture of Membranes between 34 and 37 Weeks: A Randomized Controlled Trial. PLoS Med 9(4): e1001208. doi:10.1371/journal.pmed.1001208
Academic Editor: Philippa Middleton, The University of Adelaide, Australia
Received September 5, 2011; Accepted March 16, 2012; Published April 24, 2012
Copyright:  2012 van der Ham et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The trial was funded by ZonMW (The Medical and Health Research Council of The Netherlands) grant number 94507212. The funders had no role in
study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
Abbreviations: PPROM, preterm prelabor rupture of membranes; PPROMEXIL, PPROM Expectant Management versus Induction of Labor; CI, confidence interval;
EM, expectant management; HELLP syndrome, hemolysis, elevated liver enzymes, and low platelets; IoL, induction of labor; NICU, neonatal intensive care unit;
RDS, respiratory distress syndrome; RR, relative risk
* E-mail: dpvanderham@gmail.com
" The PPROMEXIL trial group collaborators are listed in the Acknowledgments.
Management of PPROM Near Term: PPROMEXIL Trial
PLoS Medicine | www.plosmedicine.org 2 April 2012 | Volume 9 | Issue 4 | e1001208Introduction
Preterm prelabor rupture of membranes (PPROM) complicates
1%–5% of all pregnancies and accounts for 30%–40% of all
preterm deliveries [1–3]. It is associated with increased fetal and
maternal morbidity and mortality [4–7].
There is no consensus on the management of women with
PPROM between 34
+0 and 37
+0 wk. The American Congress of
Obstetricians and Gynecologists guidelines recommend induction
of labor (IoL) if PPROM occurs at or beyond 34
+0 wk of gestation
[8]. The Royal College of Obstetricians and Gynaecologists
guidelines state that delivery should be considered at 34
+0 wk of
gestation and recommend that women with PPROM who are
managed expectantly beyond 34 wk of gestation be counseled
about the increased risk of chorioamnionitis and the presumed
decreased risk of neonatal respiratory problems, admission for
neonatal intensive care, and cesarean section [9]. The Dutch
Society for Obstetrics and Gynecology guidelines advise expectant
management (EM) until 35
+0 wk and recommend discussing IoL
with the patient from 35
+0 wk onwards, whereas IoL is advocated
beyond 37
+0 wk [10]. Canadian and Australian surveys identify a
lack of consensus on management in women with PPROM
between 34
+0 and 36
+0 wk in those countries [11,12].
A recent Cochrane review on the management of PPROM
prior to 37 wk concluded that there is insufficient evidence to
guide clinical practice in the management of PPROM [7]. In view
of this lack of knowledge, we undertook a randomized controlled
trial called PPROM Expectant Management versus Induction of
Labor (PPROMEXIL).
In this trial, we tested the hypothesis that IoL reduces neonatal
sepsis without increasing neonatal morbidity due to prematurity
and without increasing the assisted delivery rate as compared to
EM in women with PPROM between 34
+0 and 37
+0 wk of
gestation.
Methods
We conducted a multicenter, parallel, open-label randomized
controlled trial in The Netherlands, in which all eight academic
and 52 non-academic hospitals participated. The study was
approved by the medical ethics committee of the Maastricht
University Medical Center, Maastricht, The Netherlands (Ref.
no. MEC 05-240, 8 March 2006). Local approval was given by the
boards of each of the participating hospitals. After the start of the
trial, no changes were made to the trial protocol or to the trial
outcome measures. The protocol has been published previously
[13]. The trial was registered in the ISRCTN register
(ISRCTN29313500; Text S1). This trial is reported in concor-
dance with the CONSORT 2010 checklist (Text S2).
Patients
Women with a singleton or twin pregnancy presenting with
PPROM between 34
+0 and 36
+6 wk of gestation who were not in
labor within 24 h after rupture of membranes were eligible for this
study. Women in whom PPROM was diagnosed after 26
+0 wk,
but who had not delivered by 34
+0 wk of gestational age were also
eligible for participation. All eligible patients were counseled about
participation in the study within the first 24 h after PPROM had
occurred. Informed consent was obtained from all who partici-
pated in the study at least 24 h after PPROM, as soon as was
possible and convenient. Breech presentation was not an exclusion
criterion, as both cesarean and vaginal delivery were allowed in
the protocol. Women with a monochorionic multiple pregnancy;
abnormal (non-reassuring) cardiotocogram; meconium-stained
amniotic fluid; signs of intrauterine infection; major fetal
anomalies; hemolysis, elevated liver enzymes, and low platelets
(HELLP syndrome); or severe preeclampsia were not eligible for
the study. Women who declined consent for randomization but
authorized use of their medical data were included in the database
and were followed in the patient preference arm.
Rupture of membranes was diagnosed based on history and
clinical findings such as gross vaginal fluid loss, in combination
with other available diagnostic test methods when necessary. The
final decision on whether or not a patient had rupture of
membranes was made by the attending staff.
Gestational age was based either on first trimester ultrasound scan
or, in women with a regular cycle, on the first day of the last
menstrual period if the expected date of delivery differed less than
7 d from that estimated by ultrasound. In womenwith anunknown/
uncontrolled pregnancy beyond the first trimester, gestational age
was estimated by second trimester ultrasound measurements.
Randomization
After written informed consent had been obtained, patient data
were entered in a password-protected web-based database.
Randomization was performed on a central password-protected
web-based application developed by the clinical trial unit of the
Academic Medical Center Amsterdam, Amsterdam, The Nether-
lands. The randomization sequence was created using a block size
of four, stratified for center and parity, in a 1:1 ratio for immediate
IoL versus EM.
Procedures
Induction of labor. Patients allocated to IoL were induced
within 24 h after randomization. Induction was performed
according to the national guidelines [14]. After vaginal
examination labor was induced with either prostaglandin or
oxytocin. In the case of planned cesarean section, the cesarean
section was performed as soon as feasible after randomization.
Expectant management. Women randomized to EM were
monitored according to local protocol until spontaneous delivery,
which could be in an outpatient or an inpatient setting.
Monitoring in both settings consisted of at least daily maternal
temperature monitoring and twice weekly blood sampling for
maternal leukocyte count and C-reactive protein measurement.
When a patient in the EM group reached 37
+0 wk of gestational
age, labor was induced according to the national guidelines [10].
Whenever a patient with an indication for planned cesarean
section was allocated to EM, the cesarean section was performed
as soon as labor commenced. Labor was induced prior to 37
+0 wk
of gestation if there were clinical signs of infection or when another
fetal or maternal indication occurred that warranted IoL.
Data Collection
At all local centers, data collection was the responsibility of the
local investigators, who were supported by regional research
nurses and midwives. Data were collected, coded, and processed
with adequate precautions to ensure patient confidentiality.
At study entry, baseline demographics and obstetric and
medical history were recorded. Ethnicity and country of birth
were recorded by patients themselves. Baseline blood samples were
taken from all participating women at study entry. A vaginal swab
was collected either at admission to the hospital or at study entry.
The national guidelines of the Dutch Society for Obstetrics and
Gynecology do not indicate whether to start or not start antibiotics
in women with PPROM prior to 37 wk [10]. Thus, antepartum
administration of antibiotics was given according to local protocol.
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recorded, including maternal and neonatal length of stay in
hospital. The placenta was sent for histological examination to
determine the presence or absence of chorioamnionitis, and
funisitis in particular. Serious adverse events were reported to the
Adverse Events Committee of the study. No interim analysis was
planned, as both treatment options were common practice.
Outcome Measures
Primary outcome. Neonatal sepsis was defined as follows: (1)
blood culture taken at birth found positive for bacteria (excluding
Staphylococcus epidermidis) or (2) two or more symptoms of infection
(apnea, temperature instability, lethargy, feeding intolerance,
respiratory distress, hemodynamic instability) within 72 h after
birth, plus one of the following: (a) positive blood culture (culture-
proven sepsis); (b) C-reactive protein .20 mmol/l (suspicion of
sepsis); (c) positive surface cultures of a known virulent pathogen
(suspicion of sepsis).
When a local investigator classified a case as sepsis, or when
criteria for sepsis were entered in the database, the case was judged
by an independent panel of pediatricians (A. L. M. M. and R. M.)
who, unaware of the allocation of randomization, adjudicated
betweenneonatalsepsis(provenorsuspectedsepsis)ornosepsis[13].
Secondary outcomes. Secondary neonatal outcome mea-
sures were respiratory distress syndrome (RDS), wet lung,
meconium aspiration syndrome, pneumothorax/pneumome-
diastinum, asphyxia, late onset neonatal sepsis, hypoglycemia,
necrotizing enterocolitis, hyperbilirubinemia, intraventricular
hemorrhage, periventricular leucomalacia, convulsions, other
neurological abnormalities, other complications, intrapartum
death, total length of hospital stay and admission, and length of
stay on neonatal intensive care unit (NICU).
Maternal outcome measures were antepartum hemorrhage,
uterine rupture, umbilical cord prolapse, signs of chorioamnionitis
(defined as fever before or during labor as a temperature greater
than 37.5uC on two occasion more than 1 h apart before or during
labor, or a temperature greater than 38.0uC on one occasion with
uterine tenderness, leukocytosis, maternal or fetal tachycardia, or a
foul-smelling vaginal discharge in absence of any other cause of
hyperpyrexia), maternal sepsis (defined as a temperature greater
than 38.5uC and a positive blood culture or circulatory instability
requiring intensive care monitoring), thromboembolic complica-
Figure 1. Trial profile.
doi:10.1371/journal.pmed.1001208.g001
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(defined as a temperature greater than 38.0uC on two occasions at
least 1 h apart after the first 24 h postpartum with associated
uterine tenderness), pneumonia, anaphylactic shock, HELLP
syndrome, maternal death, other complications, total length of
hospital stay, and admission to the intensive care unit. Finally, we
recorded mode of delivery and need for anesthesia [13].
Statistical Analysis
Sample size. The proportion of neonates with sepsis was
hypothesized to be 7.5% in the EM group and 2.5% in the IoL
group. Because it was considered clinically not plausible that IoL
would lead to a higher proportion of neonatal sepsis as compared
to EM, we performed a power analysis based on a one-sided test,
without continuity correction. This required 260 women per
Table 1. Baseline characteristics.
Characteristic
a IoL (n=266) EM (n=266)
Maternal age (range) [±SD], y 29.5 (18.3–43.3) [64.9] 29.6 (18.1–46.7) [65.6]
Number nulliparous (parity range) (percent nulliparous) 147 (0–5) (55%) 152 (0–5) (57%)
Twin pregnancy 2 (0.8%) 4 (1.5%)
Ethnic origin
White 211 (79%) 209 (79%)
Other ethnic origin 35 (13%) 45 (17%)
Unknown 20 (7.5%) 14 (5.3%)
Education
b,c
Primary school (4 to 12 y) 10 (6.6%) 0 (0%)
Secondary school (12–18 y) 11 (7.2%) 15 (9.5%)
Lower professional school 14 (9.2%) 15 (9.5%)
Medium professional school 69 (46%) 80 (51%)
Higher professional school 35 (23%) 34 (22%)
University 12 (7.9%) 14 (8.9%)
Maternal smoking 58 (23%) 63 (25%)
Antenatal administration of corticosteroids 37 (15%) 39 (15%)
Body mass index
c
At booking (range) [6SD], kg/m
2 24.8 (17.0–52.2) [65.7] 24.6 (16.4–45.1) [65.1]
At study entry (range) [6SD], kg/m
2 29.4 (16.3–52.1) [66.3] 28.7 (17.9–46.3) [65.7]
Diagnostic test for rupture of membranes
d
Positive history 224 (84%) 235 (88%)
Positive ferning 127 (48%) 133 (50%)
Positive pH test 9 (3.4%) 10 (3.8%)
Positive PAMG-1 test 17 (6.4%) 18 (6.8%)
Other positive ROM test 18 (6?8%) 10 (3?8%)
Decrease amniotic fluid on ultrasound 126 (47%) 133 (50%)
Gestational age at PPROM
,34 wk 36 (14%) 38 (14%)
34
+0 to 34
+6 wk 41 (15%) 35 (13%)
35
+0 to 35
+6 wk 79 (30%) 84 (32%)
36
+0 to 36
+6 wk 110 (41%) 109 (41%)
Gestational age at PPROM, median [IQR], d 249 [243–253] 249 [243–253]
Gestational age at randomization, median [IQR], d 251 [245–255] 251 [245–255]
Fetal position at data entry
Cephalic 251 (94%) 245 (92%)
Breech 15 (5.6%) 21 (7.9%)
Maternal temperature at inclusion, mean [±SD], 6C
c 36.9 [60.48] 36.9 [60.44]
Data are presented as number (percent) unless otherwise indicated.
aPercents given are related to available data per characteristic and may differ from total number of patients.
bPercents given as part of known educational level.
cOutcome characteristic with more than 5% missing data. Education: data available for 310 women (58%); body mass index at booking: data available for 453 women
(85%); body mass index at start study available for 266 women (50%); maternal temperature at inclusion: data available for 504 women (95%).
dSum of tests exceeds 100% because more than one test could be applied on the same patient.
IQR, interquartile range; PAMG-1, placental alpha macroglobulin-1; ROM, rupture of membranes; SD, standard deviation.
doi:10.1371/journal.pmed.1001208.t001
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with 80% power and a 5% type one error probability.
Data analysis. Data were analyzed on an intention to treat
basis. After tabulation, study baseline characteristics were
compared. Continuous data were tested with the Student’s t test
or the non-parametric Mann-Whitney U test. Relative risks (RRs),
mean differences, and 95% confidence intervals (CIs) were
calculated for the relevant outcome measures. Categorical data
were analyzed with x
2 statistics. Since the randomization was
stratified for center and parity, we performed a stratified analysis
Table 2. Pregnancy outcomes.
Outcome
a IoL (n=266/268)
b EM (n=266/270)
c
RR or Mean Difference
(95% CI; p-Value)
Absolute Risk
Reduction (95% CI)
Onset of labor
Spontaneous 38 (14%) 161 (61%) 0.24 (0.17 to 0.32; ,0.0001) 46.3% (39.0% to 53.5%)
Planned cesarean section 5 (1.9%) 14 (5.3%) 0.36 (0.13 to 0.98; 0.036) 3.3% (0.24% to 6.5%)
Induction 223 (84%) 91 (34%) 2.45 (2.06 to 2.92; ,0.0001) 249.6% (242.4% to
256.8%)
$37 wk gestational age 0 (0%) 70 (77%) NA NA
Gestational age at birth, mean [±SD]
(median) [IQR], d
250.9 [66.6] (252)
[246–256]
254.3 [65.8] (256)
[251–259]
23.34 (24.39 to 22.29;
,0.0001)
d
NA
Gestational age at birth
34
+0 to 34
+6 wk 49 (18%) 22 (8.1%) 2.24 (1.0 to 3.60; 0.0005) 210.1% (24.47% to
215.8%)
35
+0 to 35
+6 wk 79 (30%) 49 (18%) 1.62 (1.19 to 2.22; 0.002) 211.3% (24.19% to
218.5%)
36
+0 to 36
+6 wk 124 (46%) 110 (41%) 1.14 (0.94 to 1.38; 0.196) 25.53% (213.9% to
2.84%)
37
+0 to 37
+6 wk 14 (5.2%) 89 (33%) 0.16 (0.09 to 0.27; ,0.0001) 27.7% (21.5% to 34.0%)
.38 wk 2 (0.7%)
e 0 (0%) 0.155 20.75% (21.77% to
0.28%)
Interval between randomization and birth,
mean [±SD] (median) [IQR], h
38.4 [679.7] (26)
[14–38]
117 [6135] (65)
[26–141]
278.5 (297.3 to 259.7;
,0.0001)
d
NA
Interval between rupture of membranes
and birth, mean [±SD] (median) [IQR], h
103 [6140] (62)
[47–98]
202 [6234] (110)
[64–234]
298.3 (2131 to 265.2;
,0.0001)
d
NA
Mode of delivery
Vaginal, spontaneous 213 (80%) 209 (77%) 1.03 (0.94 to 1.12; 0.559) 22.07% (29.02% to
4.88%)
Vaginal, assisted 19 (7.1%)
f 24 (8.9%)
g 0.80 (0.45 to 1.42; 0.442) 1.80% (22.78% to
6.38%)
Cesarean section 36 (13%) 37 (14%) 0.98 (0.64 to 1.50; 0.927) 0.27% (25.52% to
6.06%)
Any instrumental delivery 55 (21%) 61 (23%) 0.91 (0.66 to 1.26; 0.559) 2.07% (24.88% to
9.02%)
Antibiotics
During admission 92 (35%) 92 (35%) 1.00 (0.79 to 1.26; .0.999) 0.0% (28.08% to 8.08%)
During labor 84 (32%) 73 (28%) 1.14 (0.88 to 1.48; 0.336) 23.85% (211.7% to
3.98%)
During admission or labor 112 (42%) 108 (41%) 1.04 (0.85 to 1.27; 0.725) 21.50% (29.87% to
6.86%)
Epidural and/or spinal analgesia 71 (27%) 43 (16%) 1.65 (1.18 to 2.32; 0.003) 210.5% (217.4% to
23.61%)
Hemorrhage, mean (range) [±SD], ml 420 (50–5,000) [6471] 437 (50–4,000) [6491] 217.8 (2101 to 65.1; 0.674) NA
Total maternal admission, mean [±SD]
(median) [IQR], d
9.3 [66.2] (8) [6–12] 11.3 [68.3] (9) [6–14] 21.94 (23.21 to 20.68; 0.003) NA
Data are presented as number (percent) unless otherwise indicated.
aPercents, RRs, 95% CIs, and p-values given are related to available data per characteristic and may differ from the total number of patients.
bThe number of women in the IoL group was 266; the number of newborns in the IoL group was 268.
cThe number of women in the EM group was 266; the number of newborns in the EM group was 270.
dMean difference with 95% CI.
eAfter randomization, the diagnosis rupture of membranes was reconsidered for these two women, and they were managed as having intact membranes.
fIncluding one forceps extraction.
gIncluding two forceps extractions.
IQR, interquartile range; NA, not applicable; SD, standard deviation.
doi:10.1371/journal.pmed.1001208.t002
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of neonatal sepsis is presented as RR after applying the Cochran-
Mantel-Haenszel correction. Kaplan-Meier curves were constructed
to analyze time from randomization to delivery in both study arms.
These curves were compared using the log rank test. p-Values below
0.05 were considered to indicate statistical significance. Statistical
analyses were performed using SPSS Statistics (version 17.0).
Meta-Analysis
We updated a recent Cochrane review [7] on sepsis, RDS, and
cesarean section rate. To do so, we performed an additional search
in MEDLINE and CENTRAL (from 1 October 2009 until 30
April 2011), using the same strategy as described by Buchanan et
al. in order to find additional papers that were not in the
systematic review [7]. Two authors (D. P. v. d. H. and B. W. J. M.)
identified papers for relevance and quality, and extracted the data.
We calculated risk ratios, with 95% CIs for all outcomes.
Buchanan et al. subdivided their analysis between overall sepsis
(defined or undefined by the authors) and culture-proven sepsis
[7]. They also made a comparison between suspicion of neonatal
sepsis and management of labor. In this comparison they included
one study [15]. Because of the broad definition given by the
authors of this study for suspicion of sepsis (‘‘clinical findings
suggestive for neonatal sepsis’’), we considered our definition of
suspicion of neonatal sepsis not comparable. But we considered
our overall sepsis rate as comparable with the overall sepsis rate,
and added the culture-proven sepsis cases in our study to the
culture-proven sepsis comparison in the meta-analysis.
Statistical analyses were carried out using RevMan, version 5.1
[16].
Results
From 1 January 2007 until 9 September 2009 a total of 776
women were asked to participate in the trial, of which 536 women
(69%) gave informed consent. A total of 268 women were
randomized to IoL (IoL group) and 268 to EM (EM group).
Figure 1 outlines the study profile. In both arms two patients were
excluded because after completion of the trial it became clear that
their gestational age was over 36
+6 wk at the time of inclusion.
Baseline characteristics were comparable between the two groups
(Table 1). Median gestational age at randomization was 251 d
(35
+6 wk). The percentage of women that had PPROM before
34 wk of gestation was 14% in both groups.
Table 2 shows the data on pregnancy outcome and mode of
delivery. In the EM group, labor was induced in 94 women (34%),
in 70 (77%) of these cases because the gestational age of 37 wk was
reached. In 24 women induction was prior to 37 wk, in four cases
(4.4%), this was for fetal distress, in four (4.4%) for meconium-
stained amniotic fluid, in six (6.6%) for signs of infections, in three
Figure 2. Kaplan-Meier curve for the interval between randomization and birth.
doi:10.1371/journal.pmed.1001208.g002
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other maternal complications. In the remaining two patients
(2.2%), no reason for induction was recorded. Figure 2 shows the
Kaplan-Meier curve for the interval between randomization and
delivery in both groups.
Of the 266 women allocated to the IoL group, 38 (14%) went
into labor spontaneously (i.e., after randomization but before it
was possible to start induction), five (2%) had a planned cesarean
section, and in the remaining 223 (84%) women, labor was
induced.
Women allocated to IoL obtained epidural or spinal analgesia
more often than those in the EM group, 71 (27%) versus 43 (16%),
respectively (RR 1.7; 95% CI 1.2 to 2.3). There was no difference
in antibiotic administration during admission or labor between the
Table 3. Neonatal outcomes.
Outcome
a IoL (n=268) EM (n=270)
RR or Mean Difference
(95% CI; p-Value)
Absolute Risk Reduction
(95% CI)
Primary outcome
Proven neonatal sepsis 1 (0.4%) 3 (1.1%) 0.34 (0.04 to 3.21; 0.319) 0.74% (20.71% to 2.19%)
Suspected neonatal sepsis 6 (2.2%) 8 (2.9%) 0.76 (0.27 to 2.15; 0.598) 0.72% (21.96% to 3.41%)
Sepsis overall 7 (2.6%) 11 (4.1%) 0.64 (0.25 to 1.63; 0.346) 1.46% (21.57% to 4.50%)
Secondary outcomes
Apgar score at 1 min ,7 12 (4.5%) 17 (6.4%) 0.70 (0.34 to 1.44; 0.340) 1.87% (21.97% to 5.71%)
Apgar score at 5 min ,7 2 (0.7%) 1 (0.4%) 2.02 (0.18 to 22.1; 0.558) 20.38% (21.64% to 0.89%)
Neonatal temperature .38.0uC
b 16 (11%) 6 (4.1%) 2.74 (1.10 to 6.81; 0.022) 27.06% (213.1% to 21.02%)
pH umbilical artery ,7.1 mmol/l
b 9 (4.6%) 5 (2.5%) 1.87 (0.64 to 5.47; 0.249) 22.14% (25.78% to 1.50%)
Birth weight, mean [6SD], g 2,660 (6438) 2,723 (6414) 262.7 (2135 to 9.44; 0.088)
c NA
Respiratory distress 21 (7.8%) 17 (6.3%) 1.25 (0.67 to 2.31; 0.486) 21.54% (25.57% to 2.79%)
Wet lung 2 (0.7%) 4 (1.5%) 0.50 (0.09 to 2.73; 0.417) 0.74% (21.04% 2.51%)
Asphyxia 0 (0%) 0 (0%) NA NA
Pneumothorax/pneumomediastinum 0 (0%) 1 (0.4%) 0.322 0.38% (20.37% to 1.13%)
Meconium aspiration syndrome 0 (0%) 0 (0%) NA NA
Neonatal meningitis 0 (0%) 1 (0.4%) 0.323 0.38% (20.37% to 1.14%)
Late onset sepsis 0 (0%) 1 (0.4%) 0.323 0.38% (20.37% to 1.13%)
Hypoglycemia 49 (19%) 23 (8.9%) 2.16 (1.36 to 3.43; 0.0008) 210.3% (216.2% to 24.33%)
Hyperbilirubinemia 96 (38%) 67 (26%) 1.47 (1.13 to 1.90; 0.004) 211.9% (219.9% to 23.97%)
Necrotizing enterocolitis 0 (0%) 0 (0%) NA NA
HIE grade 1 or 2 0 (0%) 0 (0%) NA NA
HIE grade 3 or 4 0 (0%) 0 (0%) NA NA
IVH grade 1 or 2
b 0 (0%) 1 (0.4%) 0.325 0.39% (20.37% to 1.15%)
IVH grade 3 or 4
b 0 (0%) 1 (0.4%) 0.325 0.39% (20.37% to 1.15%)
PVL grade 1 or 2 1 (0.4%) 0 (0%) 0.314 20.40% (21.17 to 0.38%)
PVL grade 3 or 4 0 (0%) 0 (0%) NA NA
Convulsions 0 (0%) 1 (0.4%) 0.322 0.38% (20.36% to 1.13%)
Other neurologic disorders 2 (0.8%) 3 (1.2%) 0.68 (0.11 to 4.02; 0.666) 0.37% (21.32% to 2.06%)
Other disorders 25 (9.8%) 37 (15%) 0.68 (0.42 to 1.09; 0.104) 4.69% (20.95% to 10.3%)
Intrapartum death 0 (0%) 0 (0%) NA NA
Neonatal death 0 (0%) 0 (0%) NA NA
Hospital admission 251 (94%) 253 (94%) 0.999 (0.96 to 1.05; 0.98) 0.05% (4.1% to 4.2%)
Length of hospital stay, mean [6SD]
(median) [IQR], d
8.0 [67.1] (6) [2.5–11] 6.5 [67.9] (4) [2–9] 1.4 (0.11 to 2.74; 0.034)
c NA
NICU admission 24 (9.0%) 15 (5.6%) 1.61 (0.86 to 3.00; 0.128) 23.40% (27.78% to 0.98%)
Length of NICU stay, mean [6SD]
(median) [IQR], d
4.1 [64.1] (2) [1–6] 8.1 [67.9] (5) [3–12] 23.98 (27.89 to 20.08; 0.046)
c NA
Data are presented as number (percent) unless otherwise indicated.
aPercentages, RRs, 95% CIs, and p-values given according to available data.
bOutcome characteristic with more than 5% missing data. Neonatal temperature data available for 292 infants (54%); pH umbilical artery data available for 397 (74%);
intraventricular hemorrhage data available for 508 (94%).
cMean difference with 95% CI.
HIE, hypoxic ischemic encephalopathy; IQR, interquartile range; IVH, intraventricular hemorrhage; NA, not applicable; PVL, periventricular leucomalacia; SD, standard
deviation.
doi:10.1371/journal.pmed.1001208.t003
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groups (36 [13%] cesarean sections in the IoL group versus 37
[14%] in the EM group; RR 0.98; 95% CI 0.64 to 1.5). No serious
adverse events were reported during the study period.
Neonatal Sepsis
Neonatal sepsis was seen in seven newborns (2.6%) in the IoL
group versus 11 (4.1%) in the EM group (RR 0.64; 95% CI 0.25 to
1.6) (see Table 3). The RR for neonatal sepsis was similar when
stratified for center and parity (RR 0.65; 95% CI 0.25 to 1.7).
Other Neonatal Outcomes
Table 3 shows all neonatal outcomes. Neonates born in the IoL
group stayed 1.4 d longer in hospital than neonates born after EM
and were admitted more often to the NICU. Newborns admitted
to the NICU in the IoL group stayed shorter than those in the EM
group.
RDS was seen in 21 (7.8%) newborns in the IoL group versus 17
(6.3%) in the EM group. Hypoglycemia (RR 2.2) and hyperbil-
irubinemia (RR 1.5) were seen significantly more often in the IoL
group. For other neonatal outcome measures, there were no
significant differences between the two groups. Seventy-six
newborns (28%) in the IoL group were treated with antibiotics,
for an average of 5.0 d, versus 78 (27%) in the EM group, for an
average of 5.0 d (Table 4).
Maternal Outcomes
Table 5 shows the maternal outcomes. Clinical chorioamnio-
nitis was seen in six women (2.3%) in the IoL group versus 15
(5.6%) women in the EM group (RR 0.40; 95% CI 0.16 to 1.02).
Table 4. Neonatal treatments.
Outcome
a IoL (n=268) EM (n=270)
RR or Mean Difference
(95% CI; p-Value)
Absolute Risk
Reduction (95% CI)
Antibiotic treatment, number (percent)
Augmentin 12 (4.5%) 18 (6.7%) 0.67 (0.33 to 1.37; 0.270) 2.19% (21.68% to
6.06%)
Amoxicillin 49 (18%) 55 (20%) 0.90 (0.64 to 1.27; 0.540) 2.09% (24.58% to
8.76%)
Gentamycin 44 (16%) 45 (17%) 0.99 (0.67 to 1.44; 0.938) 0.25% (26.03% to
6.53%)
Cephalosporin 10 (3.7%) 9 (3.3%) 1.12 (0.46 to 2.71; 0.803) 20.40% (23.52% to
2.72%)
Other antibiotics 25 (9.3%) 19 (7.0%) 1.33 (0.75 to 2.35; 0.332) 22.29% (26.92% to
2.34%)
Any antibiotic treatment 76 (28%) 75 (28%) 1.02 (0.78 to 1.34; 0.881) 20.58% (28.17% to
7.01%)
Antibiotic treatment length, mean (±SD)
b
Augmentin 4.5 (62.3) 5.2 (62.5) 20.72 (22.57 to 1.13; 0.430)
c NA
Amoxicillin 4.8 (62.8) 5.2 (62.5) 20.46 (21.50 to 0.57; 0.377)
c NA
Gentamycin 4.4 (61.9) 3.7 (61.6) 0.68 (20.07 to 1.42; 0.076)
c NA
Cephalosporin 4.7 (63.8) 5.4 (62.2) 20.74 (23.83 to 2.34; 0.617)
c NA
Other antibiotics 4.8 (62.7) 5.1 (62.7) 20.25 (21.97 to 1.46; 0.768)
c NA
Any antibiotic treatment 5.1 (62.8) 5.1 (62.5) 20.01 (20.86 to 0.84; 0.974)
c NA
Other neonatal treatment, number (percent)
Positive pressure ventilation with endotracheal tube 2 (0.7%) 4 (1.5%) 0.50 (0.09 to 2.73; 0.417) 0.73% (21.04% to
2.51%)
Positive pressure ventilation 11 (4.1%) 9 (3.3%) 1.23 (0.52 to 2.92; 0.636) 20.77% (23.97% to
2.43%)
Tube feeding 37 (14%) 33 (12%) 1.13 (0.73 to 1.75; 0.585) 21.58% (27.27% to
4.10%)
Total parenteral feeding 5 (1.9%) 5 (1.9%) 1.007 (0.30 to 3.44; 0.991) 20.01% (22.29% to
2.27%)
Other neonatal treatment length, mean (±SD)
d
Positive pressure ventilation with endotracheal tube 2.0 (61.4) 2.5 (61.3) 20.50 (23.68 to 2.68; 0.685)
c NA
Positive pressure ventilation 3.1 (62.9) 1.8 (60.97) 1.40 (20.77 to 3.58; 0.191)
c NA
Tube feeding 8.1 (64.5) 6.0 (64.2) 2.16 (0.07 to 4.25; 0.043)
c NA
Total parenteral feeding 5.2 (62.7) 7.2 (69.8) 2.00 (212.5 to 8.51; 0.672)
c NA
aPercentages given according to available data.
bMean treatment length calculated for neonates receiving each antibiotic.
cMean difference with 95% CI.
dMean treatment length calculated from neonates receiving each treatment.
NA, not applicable; SD, standard deviation.
doi:10.1371/journal.pmed.1001208.t004
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versus 62 (32%), respectively (RR 0.69; 95% CI 0.49 to 0.96).
Non-Randomized Women
Table 6 shows the baseline characteristics of the 207 non-
randomized women. The non-randomized women differed to
those randomized in level of education (more educated), smoking
(fewer smoked), maternal age (older), and management (preferred
EM). Furthermore, they differed in gestational age at PPROM
(earlier PPROM). Neonatal sepsis was seen in one of 13 (7.7%)
neonates born to mothers who preferred IoL, and in seven of the
198 (3.5%) neonates born to mothers who chose EM.
Meta-Analysis
The electronic search yielded ten new results relevant for meta-
analysis. After reviewing these papers, none fulfilled the inclusion
criteria. Figure 3 presents the results of the meta-analysis including
our own data. In total, 1,230 neonates could be analyzed from
eight studies for neonatal sepsis, 892 neonates (five studies) for
culture-proven sepsis, 1,230 neonates (eight studies) for RDS, and
1,222 women (eight studies) for cesarean section rate. None of the
risk ratios for these outcomes were statistically different (1.06 [95%
CI 0.64–1.76], p=0.81; 0.94 [95% CI 0.43–2.05], p=0.87; 1.03
[95% CI 0.80–1.33], p=0.83; 1.27 [95% CI 0.98 to 1.65],
p=0.07, respectively).
Discussion
We conducted a large randomized study (the PPROMEXIL
trial) to compare IoL and EM in women with PPROM between
34 and 37 wk of gestational age. Because of the conservative
treatment policy and conservative preferences amongst patients in
The Netherlands, we had an ideal population in which to perform
this trial, with extensive data on all eligible patients including non-
participants (31%), the vast majority of whom declined participa-
tion because they preferred EM.
Table 5. Maternal outcomes.
Outcome
a IoL (n=266) EM (n=266) RR (95% CI; p-Value) Absolute Risk Reduction (95% CI)
Maternal complications
Antepartum hemorrhage 2 (0.8%) 5 (1.9%) 0.40 (0.08 to 2.04; 0.255) 1.13% (20.81% to 3.06%)
Cord prolapse 1 (0.4%) 0 (0%) 0.319 20.38% (21.11% to 0.36%)
Uterine rupture 1 (0.4%) 0 (0%) 0.319 20.38% (21.11% to 0.36%)
Clinical chorioamnionitis 6 (2.3%) 15 (5.6%) 0.40 (0.16 to 1.02; 0.045) 3.38% (0.09% to 6.68%)
Sepsis 6 (2.3%) 1 (0.4%) 6.00 (0.72 to 49.5; 0.057) 21.88% (23.81% to 0.05%)
Thromboembolic complications 0 (0%) 1 (0.4%) 0.319 0.38% (20.36% to 1.11%)
Urinary tract infections treated with
antibiotics
4 (1.5%) 0 (0%) 0.045 21.50% (22.97% to 20.04%)
Endometritis 2 (0.8%) 4 (1.5%) 0.50 (0.09 to 2.71; 0.412) 0.75% (21.04% to 2.55%)
Pneumonia 0 (0%) 1 (0.4%) 0.319 0.38% (20.36% to 1.11%)
Anaphylactic shock 0 (0%) 0 (0%) NA NA
HELLP syndrome 0 (0%) 2 (0.8%) 0.157 0.75% (20.29% to 1.79%)
Death 0 (0%) 0 (0%) NA NA
Other complications 11 (4.1%) 9 (3.4%) 1.22 (0.52 to 2.90; 0.649) 20.75% (23.98% to 2.48%)
Perineum
No laceration 116 (44%) 114 (43%) 1.02 (0.84 to 1.24; 0.831) 20.92% (29.35% to 7.51%)
First degree laceration 49 (19%) 52 (20%) 0.95 (0.67 to 1.34; 0.756) 1.06% (25.62% to 7.73%)
Second degree laceration 27 (10%) 35 (13%) 0.77 (0.48 to 1.24; 0.288) 2.97% (22.49% to 8.43%)
Third degree laceration 2 (0.8%) 2 (0.8%) 1.004 (0.14 to 7.07; 0.997) 0.003% (21.47% to 1.47%)
Fourth degree laceration 2 (0.8%) 4 (1.5%) 0.50 (0.09 to 2.72; 0.414) 0.75% (21.05% to 2.55%)
Episiotomy 69 (26%) 59 (22%) 1.17 (0.87 to 1.59; 0.301) 23.86% (211.1% to 3.41%)
Delivery of placenta
Spontaneous 211 (79%) 209 (79%) 1.01 (0.92 to 1.10; 0.832) 20.75% (27.68% to 6.18%)
Manual placental removal 19 (7.1%) 20 (7.5%) 0.95 (0.52 to 1.74; 0.868) 20.38% (24.05% to 4.81%)
During cesarean section 36 (14%) 37 (14%) 0.97 (0.64 to 1.49; 0.900) 0.38 (25.47% to 6.22%)
Chorioamnionitis
Histological chorioamnionitis
b 43 (22%) 62 (32%) 0.69 (0.49 to 0.96; 0.026) 9.86% (1.22% to 18.5%)
Histological funisitis
b 21 (11%) 34 (18%) 0.61 (0.36 to 1.004; 0.048) 6.99% (0.07% to 13.9%)
Other complications 16 (6.0%) 15 (5.6%) 1.07 (0.54 to 2.11; 0.853) 20.38% (24.36% to 3.61%)
Data are presented as number (percent).
aPercents, RRs, 95% CIs, and p-values given are related to available data per characteristic and may differ from the total number of patients.
bOutcome characteristic with more than 5% missing data. Histological chorioamnionitis data available for 396 women (74%); histological funisitis data available for 388
women (73%).
doi:10.1371/journal.pmed.1001208.t005
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34 and 37 wk of gestation, IoL does not substantially reduce the
incidence of neonatal sepsis compared to EM. The number of
neonates with respiratory distress was comparable in both arms,
and IoL did not increase the risk of a cesarean section, findings
that were confirmed in meta-analysis. However, in our study IoL
increased the risk of hypoglycemia and hyperbilirubinemia, as well
as the use of epidural or spinal analgesia during labor.
Our findings are in line with the results of the TERMPROM
trial, which compared IoL with EM in 5,041 women with prelabor
rupture of membranes at term [17]. The TERMPROM trial
showed that IoL did not reduce the risk of neonatal sepsis as
compared to EM (2.5% versus 2.8%) [17].
In contrast to earlier studies [15,17–19], our pragmatic protocol
did not include routine cultures from all neonates to diagnose
sepsis. Because of the lack of consensus amongst Dutch
neonatologists on whether to take blood samples routinely after
prolonged premature rupture of membranes, neonatal blood
samples and liquor cultures were taken only on clinical indication.
All cases with any possible sign of neonatal sepsis were adjudicated
by a panel of neonatologists. In consensus they decided whether or
not a newborn had suffered neonatal sepsis (suspected or proven).
Despite of the lack of blood culture from all neonates in the trial,
we believe that no cases of neonatal sepsis were missed and that
the incidence of neonatal sepsis was not overestimated.
IoL reduced the risk of chorioamnionitis. Several studies have
demonstrated a relationship between chorioamnionitis and
adverse neonatal outcome [20–23]. In a large study of very
premature neonates (,28 wk; the ELGAN study) [20], a
relationship between cerebral palsy and/or white matter damage
and positive bacteriological cultures from the placenta was
demonstrated. Other studies have also described a relationship
between chorioamnionitis and increased risk for sepsis, respiratory
distress, pneumonia, and even neonatal death [22,23]. We doubt,
however, that these findings can be extrapolated to our
population. The incidence of cerebral palsy is significantly lower
in the near-term-birth population, and reported incidences of
adverse neonatal outcome in a near-term and term newborns are
Table 6. Baseline characteristics for randomized versus non-randomized participants.
Characteristic
a Randomized (n=532) Non-Randomized (n=207) p-Value
Maternal age (range) [±SD], y 29.6 (18.0–46.7) [65.3] 32.3 (19.5–45.5) [65.0] ,0.0001
Number nulliparous (parity range) (percent nulliparous) 299 (0–5) (56%) 121 (0–3) (58%) 0.580
Twin pregnancy 6 (1.1%) 4 (1.9%) 0.395
Ethnic origin
White 420 (79%) 149 (72%)
Other ethnic origin 78 (15%) 37 (18%) 0.188
Unknown 34 (6.4%) 21 (10%) NA
Education
b,c
Primary school (4 to 12 y) 10 (3.2%) 0 (0%)
Secondary school (12–18 y)
b 26 (8.4%) 10(8.7%)
Lower professional school 29 (9.4%) 5 (4?4%)
Medium professional school 149 (48%) 42 (37%)
Higher professional school 70 (23%) 37 (32%)
University 26 (8.4%) 21 (18%) 0.002
Maternal smoking 121 (24%) 21 (11%) 0.001
Body mass index
c
At booking (range) [6SD], kg/m
2 24.7 (16.4–52.2) [65.4] 24.4 (17.3–41.9) [64.5] 0.605
At study entry (range) [6SD], kg/m
2 29.1 (16.3–52.1) [66.0] 28.0 (17.3–43.8) [64.7] 0?139
Gestational age at PPROM
,34 wk 74 (14%) 60 (29%)
34
+0 to 34
+6 wk 76 (14%) 38 (18%)
35
+0 to 35
+6 wk 163 (31%) 64 (31%)
36
+0 to 36
+6 wk 219 (41%) 44 (21%) ,0.0001
Gestational age at PPROM, median [IQR], d 249 [243–253] 244 [234–250] ,0.0001
Maternal temperature at inclusion, mean [±SD],6C
c 36.9 [60.46] 36.8 [60.46] 0.214
Treatment
IoL 266 (50%) 13 (6.3%)
EM 266 (50%) 194 (94%) ,0.0001
Data are presented as number (percent) unless otherwise indicated.
aPercents given are related to available data per characteristic and may differ from the total number of patients.
bPercents given as part of known educational level.
cOutcome characteristic with more than 5% missing data. Education: data available for 425 women (58%); body mass index at booking: data available for 616 women
(83%); body mass index at start study available for 346 women (47%); maternal temperature at inclusion: data available for 689 women (93%).
doi:10.1371/journal.pmed.1001208.t006
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doi:10.1371/journal.pmed.1001208.g003
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onitis group) [23].
In line with the TERMPROM trial, the number of cesarean
sections in our study was comparable in the IoL and EM groups
[17]. We could not confirm the trend for increased risk on
cesarean section in the EM group that was reported in the
previous systematic review [7].
The risks of hypoglycemia and hyperbilirubinemia were decreased
inchildrenofwomentreatedexpectantly.Thesefindingshave,toour
knowledge,not previously been reported for a prospective study. In a
recent retrospective study in three tertiary hospitals in France, a
similar incidence of hyperbilirubinemia (37% for IoL versus 33% for
EM) and a slightly lower incidence of hypoglycemia (12% for IoL
versus 6% for EM) was found, but due to a lack of power, differences
were not statistically significant in the French study [24].
We doubt whether prolongation of pregnancy, which was on
average 3.3 d longer in the EM group in our trial, will have solely
contributed to the decreased risk of hypoglycemia and hyperbil-
irubinemia. Maybe spontaneous onset of labor enhances the speed
of physiological maturing by means of a still unknown adapta-
tional process, as is known to happen in the lungs, reducing the
incidence of RDS in spontaneous delivery compared to elective
cesarean section [25].
The clinical importance of these findings for later (cognitive and
motor) development in children is not clear at present for our
study group, although it is known that following symptomatic
neonatal hypoglycemia, more than 50% of infants demonstrate
cognitive and motor impairments at the age of 18 mo [26]. In low-
birth-weight infants, even an asymptomatic moderate hypoglyce-
mia may lead to cognitive and motor impairments at the age of
18 mo [27]. Hyperbilirubinemia is potentially neurotoxic, espe-
cially in infants born preterm [28]. When treated appropriately,
however, bilirubin levels under 30 mg/dl are not associated with
adverse neurodevelopmental outcome [29].
MacKay et al. [30] reported on the increased need for special
education in preterm-delivered infants. In a retrospective cohort
study of 407,503 schoolchildren, they showed that gestational age
at delivery had a strong, dose-dependent relationship with special
educational need. Until further evidence becomes available, the
decreased risk of special educational need with advancing
gestational age should be taken into account when considering
how best to manage PPROM.
Within the Dutch Consortium for Women’s Health and Repro-
ductivity Studies (http://www.studies-obsgyn.nl), the PPRO-
MEXIL trial is the largest trial so far with regard to the number
of participating hospitals (60 out of 98 eligible hospitals, 61%). The
207 non-randomized women in our study who allowed data
collection differed from the randomized women. Similar to two
other Dutch consortium trials (HYPITAT and DIGITAT)
[31,32], the women who agreed to be randomized differed in
level of education, smoking habits, maternal age, and preferred
management from those who did not agree to be randomized. The
non-randomized subgroup of women who preferred IoL was too
small to draw any conclusions from. In the EM subgroup, no
differences were seen in the primary outcome or the secondary
neonatal and maternal outcomes. Even though some women
eligible to participate in the trial did not, we believe that we did
not miss a significant group at a higher (or lower) risk for neonatal
sepsis who were treated expectantly. Despite some differences in
baseline characteristics, we assume that the results of our study can
be generalized to at least the Dutch/Western European popula-
tion. Because of wide differences in general health care and
availability of antibiotics, it is likely that these results cannot be
generalized to low-income countries.
The main limitation of our study is that it proved to be
underpowered. We hypothesized a decrease in neonatal sepsis rate
of 7.5% to 2.5%, but found a difference of only 1.5% (2.6% in the
IoL group versus 4.1% in the EM group). The liberal use of
antibiotic therapy before or during labor (41% of all participating
women received antibiotics) might have contributed to a lower
incidence compared to the other trials in which antibiotics were
not administered prophylactically [15,18,33–37]. These previous
studies showed high rates of neonatal sepsis with EM. Similarly,
improved health care may have contributed to a reduction of the
incidence of neonatal sepsis in women with PPROM over the last
decades.
In our study the observed difference in sepsis rates between the
EM and IoL groups did not reach statistical significance. Although
this study is one of the largest published so far, our sample size
was insufficient to demonstrate small differences. In retrospect,
anticipating a risk reduction of 66% (a difference in neonatal
sepsis rate of 7.5% versus 2.5%) might have been too optimistic.
However, several previous studies [18,33,35] showed neonatal
sepsis incidences up to 9.5% with EM, and we did observe an
incidence near 2.5% in the IoL group. Although optimistic, we
feel that our hypothesized risk reduction was not unrealistic.
Furthermore, we used a one-sided test for the power calculation.
We considered it not plausible that IoL in women with PPROM
near term would increase the proportion of cases of neonatal
sepsis. In retrospect, considering the results of the meta-analysis,
one might question this choice of a one-sided test, as several studies
in the meta-analysis show an increased risk for sepsis in the IoL
group. However, the analysis was executed exactly as planned in
advance. Two-sided testing would have required a sample size that
would not have been feasible in our setting, in view of the
limitations set by our funding body.
A second potential limitation is that EM prolonged gestation by
just 4 d. This rather small difference might be partly due to the
fact that the median gestational age at rupture of membranes
was 35
+4 wk and median gestational age at randomization was
35
+6 wk. The overrepresentation of women beyond the 35
th com-
pleted week of gestation was caused by the fact that women in
their 35
th week of gestation more often refused to participate
(mean gestational age at PPROM in the non-randomized group
was 34
+6 wk), and before our study an expectant policy was the
standard. Furthermore, hesitation of clinicians to induce labor
before 35 completed weeks of gestation, which prior to the start of
the PPROMEXIL trial was not recommended in the Dutch
guidelines, might also have influenced this outcome.
A third limitation of this study is that we reported many
secondary, mostly neonatal, outcomes. Although this is not
uncommon in studies in maternal–fetal medicine, it is possible
that a significant difference can be found by chance. If one applies
a Bonferroni correction to the p-value, the adjusted threshold is
p,0.001. By applying this threshold, the incidence of hypoglyce-
mia (p=0.0008) remains the only statistically significant difference
between the groups.
We are aware of the ongoing multicenter PPROMT trial
(ISRCTN44485060), which has a design similar to that of our
study. That trial may possibly answer the question whether IoL in
women with near-term PPROM reduces the risk of neonatal sepsis
[38]. However, the updated meta-analysis clearly demonstrates
that the incidence of neonatal sepsis is comparable in both
treatment strategies [38]. We therefore plan to perform an
individual patient data meta-analysis on the management of
PPROM. Combining large trials in an individual patient data
meta-analysis would, in our opinion, produce the best currently
available evidence for the management of PPROM. We have
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and will contact researchers from other published trials to
collaborate in an individual patient data meta-analysis.
We conclude that in pregnancies complicated by PPROM
between 34 and 37 wkofgestation the incidenceofneonatal sepsis is
low. Neither our trial nor the updated meta-analysis shows that IoL
substantially improves pregnancy outcomes compared with EM.
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Background. Most pregnancies last around 40 weeks, but
in industrialized countries, 5%–10% of babies are born
before 37 weeks of gestation (gestation is the period during
which a baby develops in its mother’s womb). Premature
birth is a major cause of infant death in many developed
countries, and preterm babies can also have short- and/or
long-term health problems such as breathing problems,
increased susceptibility to life-threatening infections, and
learning and developmental disabilities. There are many
reasons why some babies are born prematurely, but preterm
prelabor rupture of the membranes (PPROM) accounts for
30%–40% of preterm deliveries. Inside the womb, the baby is
held in a fluid-filled bag called the amniotic sac. The amniotic
fluid cushions the baby, helps some of its organs develop,
and protects both mother and baby from infection. The
membranes that form the sac usually break at the start of
labor (‘‘water breaking’’), but in PPROM, the membranes
break before the baby is fully grown. PPROM increases the
mother’s risk of a womb infection called chorioamnionitis
and the baby’s risk of neonatal sepsis (blood infection), and
can trigger early labor.
Why Was This Study Done? There is currently no
consensus on how to manage women whose membranes
rupture between 34 and 37 weeks’ gestation. Some
guidelines recommend immediate induction of labor if
PPROM occurs at or beyond 34 weeks’ gestation. Others
recommend that labor not be induced unless the mother
develops signs of infection such as a high temperature or has
not delivered her baby spontaneously by 37 weeks’
gestation (expectant management). Before 34 weeks’
gestation, expectant management is generally recom-
mended. In this randomized controlled trial, the re-
searchers compare the effects of induction of labor and of
expectant management on the rate of neonatal sepsis (the
proportion of babies that develop neonatal sepsis; the trial’s
primary outcome) and on secondary outcomes such as the
rates of neonatal respiratory distress syndrome (RDS),
cesarean section (surgical delivery), and chorioamnionitis in
women with PPROM between 34 and 37 weeks’ gestation.
The researchers also undertake a meta-analysis of published
trials on the effect of both interventions on pregnancy
outcomes. A randomized controlled trial compares the
effects of different interventions in groups of individuals
chosen through the play of chance; meta-analysis is a
statistical approach that combines the results of several
trials.
What Did the Researchers Do and Find? In the PPROM
Expectant Management versus Induction of Labor
(PRROMEXIL) trial, 532 non-laboring women with PPROM
between 34 and 37 weeks’ gestation were randomly
assigned to either immediate induction of labor or
expectant management. Neonatal sepsis occurred in seven
babies born to women in the induction of labor group and in
11 babies born to women in the expectant management
group. This difference was not statistically significant. That is,
it could have happened by chance. Similarly, although more
babies born to women in the induction of labor group than
in the expectant management group developed RDS (21 and
17 babies, respectively), this difference was not significant.
Cesarean section rates were similar in both intervention
groups, but the risk of chorioamnionitis was slightly reduced
in the induction of labor group compared to the expectant
management group. Finally, the researchers’ meta-analysis
(which included these new results) found no significant
differences in the risk of neonatal sepsis, RDS, or cesarean
section associated with the two interventions.
What Do These Findings Mean? These findings show
that, compared to expectant management, induction of
labor did not reduce the incidence of neonatal sepsis in
pregnancies complicated by PPROM between 34 and 37
weeks’ gestation. However, because fewer babies than
expected born to the women in the expectant manage-
ment group developed neonatal sepsis, this trial was
underpowered. That is, too few women were enrolled in
the trial to enable the detection of a small difference
between the interventions in the neonatal sepsis rate. These
findings also show that induction of labor did not sub-
stantially affect most of the secondary outcomes measured
by the researchers. Given these results and those of their
meta-analysis, the researchers conclude that, in women
whose pregnancy is complicated by PPROM late in
pregnancy, induction of labor does not substantially
improve the outcome for either the woman or her baby
compared to expectant management.
Additional Information. Please access these web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001208.
N The March of Dimes, a nonprofit organization for
pregnancy and baby health, provides information on
preterm birth (in English and Spanish); its News Moms
Need blog contains a post on PPROM
N Tommy’s is a nonprofit organization that funds research
and provides information on the causes and prevention of
miscarriage, premature birth, and stillbirth
N The Royal College of Obstetricians and Gynaecologists
guidelines on the diagnosis, investigation, and
management of PPROM are available (in English and
Russian)
N Information about the PPROMEXIL trial is available
N Personal stories about PPROM are available on the
Austprem web site, a non-profit organization that provides
information about prematurity and support for parents of
premature babies in Australia
N MedlinePlus provides links to other information on
premature babies (in English and Spanish)
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